New class

• Entire new class of small molecule antibiotics
• New mechanism of action independent to present resistance mechanisms of MDR bacteria

High potency

• Bactericidal against both Gram-positive and Gram-negative MDR bacteria
• Effective against e.g. ESKAPE pathogens 

Single or combined use

• Effective as monotherapy
• Strong synergistic interaction with common antibiotics by reversing microbial resistance at sub-MIC levels

Safety   

• Promising safety and tolerability profile with no observed adverse effect level (NOAEL)
• No CNS effect
• Excellent PK/PD properties in preclinical tests

Simple

• Easy to manufacture small molecules
• Stable compounds
• Low cost of production

 IV/oral switch

• High bioavailability
• Suitable for IV/oral switch therapy
• Multiple potential routes of administration

Excellent Market Potential

• Addresses significant unmet clinical need
• Large, growing market for antibiotics against MDR infections
• Strong platform for future development

Strong IP

• Comprehensive patent portfolio (2025-2035 ++)
• Full freedom to operate

Qualifies for GAIN

• Eligible for priority review and fast track approval
• Extension of market exclusivity